Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $17.24 and last traded at $18.22, with a volume of 728218 shares traded. The stock had previously closed at $17.94.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on SYRE shares. The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 18th. Wedbush reiterated an "outperform" rating and set a $65.00 target price on shares of Spyre Therapeutics in a research report on Monday, January 13th. Finally, Robert W. Baird increased their target price on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $54.83.
View Our Latest Stock Analysis on Spyre Therapeutics
Spyre Therapeutics Trading Down 4.9 %
The business's fifty day simple moving average is $22.00 and its 200 day simple moving average is $26.61. The stock has a market cap of $1.17 billion, a P/E ratio of -2.61 and a beta of 2.98.
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping analysts' consensus estimates of ($0.89) by $0.08. On average, analysts predict that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC raised its holdings in Spyre Therapeutics by 64.7% during the 3rd quarter. Barclays PLC now owns 105,467 shares of the company's stock worth $3,101,000 after buying an additional 41,424 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in Spyre Therapeutics during the 4th quarter worth approximately $290,000. Charles Schwab Investment Management Inc. raised its holdings in Spyre Therapeutics by 239.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 333,275 shares of the company's stock worth $9,802,000 after buying an additional 235,094 shares during the period. Jane Street Group LLC raised its holdings in Spyre Therapeutics by 78.7% during the 3rd quarter. Jane Street Group LLC now owns 20,641 shares of the company's stock worth $607,000 after buying an additional 9,090 shares during the period. Finally, State Street Corp raised its holdings in Spyre Therapeutics by 9.4% during the 3rd quarter. State Street Corp now owns 1,541,555 shares of the company's stock worth $45,337,000 after buying an additional 131,896 shares during the period. Institutional investors own 80.39% of the company's stock.
About Spyre Therapeutics
(
Get Free Report)
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Further Reading
Before you consider Spyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.
While Spyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
